The ARHGAP4 Knockout HT29 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population derived from the HT29 human colorectal adenocarcinoma cell line, featuring disruption of the ARHGAP4 gene. This polyclonal format provides a heterogeneous collection of loss-of-function alleles, offering a robust model for studying ARHGAP4 function without the artifacts of monoclonal selection. The knockout cells are suitable for analyzing the gene’s role in actin dynamics, cell migration, and Rho GTPase signaling in a colorectal cancer background.
HT29 cells are an adherent epithelial line originally isolated from a primary colorectal adenocarcinoma of a 44-year-old female. They retain the capacity for enterocytic differentiation and are widely used to investigate intestinal cell biology, including mucosal barrier function and cancer progression. The line harbors oncogenic mutations (e.g., APC, TP53), providing a clinically relevant platform to examine tumorigenic mechanisms and therapeutic responses.
ARHGAP4 encodes a GTPase-activating protein that accelerates GTP hydrolysis on Rho family GTPases RhoA, Rac1, and Cdc42, converting them to an inactive GDP-bound state. Its expression is regulated by transcription factors GATA1 and SPI1, and its activity can be influenced by Src kinases and cytokines like IL-2. Through inactivation of these GTPases, ARHGAP4 suppresses downstream effectors such as WASP, ARP2/3, focal adhesion kinase (FAK), and the adaptor NCK1, thereby coordinating actin polymerization, adhesion, and immune synapse dynamics.
In HT29 cells, ARHGAP4 knockout is predicted to increase active RhoA, Rac1, and Cdc42 levels, enhancing actin stress fiber formation and lamellipodia-driven migration. This may promote heightened cell motility and invasiveness, contributing to metastatic potential. The model allows dissection of altered integrin signaling and cell-matrix interactions, and can be applied in co-culture systems to explore immune-related functions given ARHGAP4’s role in hematopoietic cells. Its polyclonal nature ensures phenotypes reflect population-level effects.
Typical research applications include biochemical assays such as Rho GTPase pull-downs, Western blotting, and phospho-protein analysis to quantify signaling changes. Functional assays??wound healing, Transwell invasion, immunofluorescence for F-actin, and cell adhesion and proliferation assays??enable comprehensive phenotypic characterization. The model also supports pharmacological screening and genetic interaction studies targeting ARHGAP4-related pathways. For further information and technical support, please contact Ascent Research.
